Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth

Executive Summary

Baxalta's hemophilia franchise immediately becomes Shire's top seller, but the specialty firm enjoyed sales growth across its business areas. Meanwhile, the launch of Xiidra is off to an impressive start in market share and patient access.

Advertisement

Related Content

Stockwatch: Limited Acquisition Headroom At Specialty Pharma
Emicizumab Data Has Shire And Novo Looking Over Their Shoulders
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register